AV-7909 is under clinical development by Emergent BioSolutions and currently in Pre-Registration for Anthrax. According to GlobalData, Pre-Registration drugs for Anthrax have a 100% phase transition success rate (PTSR) indication benchmark for progressing into Marketed. GlobalData’s report assesses how AV-7909’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
AV-7909 (NuThrax) is under development for the prevention of anthrax. The therapeutic candidate is administered intramuscularly. AV-7909 comprises of BioThrax (anthrax vaccine adsorbed) in combination with the immunostimulatory oligodeoxynucleotide compound CPG 7909 (vaximmune). The therapeutic candidate is a third generation anthrax vaccine.
Emergent BioSolutions overview
Emergent BioSolutions (Emergent) is a life sciences company that provides specialized products to address medical needs and public health threats (PHTs). Its solutions help address PHTs including chemical, biological, radiological, nuclear and explosives (CBRNE), emerging infectious diseases, travel health, emerging health crises, and acute/emergency care. It offers vaccines, therapeutics, drug-device combination products, and contract development and manufacturing services. Emergent’s pipeline candidates target dengue and other influenza infections. It also offers specialized products to governments and commercial customers. The company distributes its products in the US and Canada through its commercial sales forces and third-party distributors. Emergent is headquartered in Rockville, Maryland, the US.
For a complete picture of AV-7909’s drug-specific PTSR and LoA scores, buy the report here.